Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy

Terpos, E. (Evangelos); Kostopoulos, I.V. (Ioannis V.); Kastritis, E. (Efstathios); Ntanasis-Stathopoulos, I. (Ioannis); Migkou, M. (Magdalini); Rousakis, P. (Pantelis); Argyriou, A.T. (Alexandra T.); Kanellias, N. (Nikolaos); Fotiou, D. (Despina); Eleutherakis-Papaiakovou, E. (Evangelos); Gavriatopoulou, M. (Maria); Ziogas, D.C. (Dimitrios C.); Papanota, A.M. (Aristea-Maria); Spyropoulou-Vlachou, M. (Marilyn); Trougakos, I.P. (Ioannis P.); Tsitsilonis, O.E. (Ourania E.); Paiva, B. (Bruno); Dimopoulos, M.A. (Meletios A.)

Palabras clave :

Minimal residual disease (MRD)
Phenotypic profiles
Suitable method
Next-generation flow (NGF)

Fecha de publicación :

2019

Editorial :

Ovid Technologies (Wolters Kluwer Health)

ISSN :

2572-9241

Nota:

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)

Cita:

Terpos, E. (Evangelos); Kostopoulos, I.V. (Ioannis V.); Kastritis, E. (Efstathios); et al. "Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy". HemaSphere. 3 (6), 2019, e300

Resumen

Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts’ and tumor-associated monocytes/macrophages’ predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10−6.

URI :

https://hdl.handle.net/10171/62276

DOI:

10.1097/HS9.0000000000000300

Aparece en las colecciones:

DA - CIMA - Hemato-oncología - Mieloma - Artículos de Revista
DA - CUN - Oncología médica - Artículos de revista

Ficheros en este ítem: